Plasma concentration and efficacy of tolvaptan in cirrhotic patients with refractory ascites.

Abstract

To investigate the relationship between the exposure and efficacy of tolvaptan, we measured pharmacokinetics of total drug at 7 days after repeated doses of 3.75 mg/day tolvaptan in 16 patients with hepatic edema. Nine patients (56.3%) were responders, which were defined as those with body weight reduction of >1.5 kg/week. Serum albumin levels were significantly lower in responders than in non-responders (P = 0.031). However, the pharmacokinetics varied greatly among individuals and was not relevant to the clinical response.

• Authors: Eri Sagawa, Hironao Okubo, Hitoshi Ando, Yushi Sorin, Ryo Kanazawa, Eisuke Nakadera, Hiroo Fukada, Shigehiro Kokubu, Akihisa Miyazaki
• Journal: Journal of pharmacological sciences (J Pharmacol Sci) Vol. 139 Issue 4 Pg. 373-376 (Apr 2019) ISSN: 1347-8648 [Electronic] Japan
• PMID: 30857764 (Publication Type: Journal Article)
• Copyright: Copyright © 2019 The Authors. Production and hosting by Elsevier B.V. All rights reserved.

Chemical References

• Antidiuretic Hormone Receptor Antagonists
• Serum Albumin
• Tolvaptan

Topics

• Adult
• Aged
• Aged, 80 and over
• Antidiuretic Hormone Receptor Antagonists (blood, pharmacokinetics, therapeutic use)
• Ascites (complications, drug therapy, metabolism)
• Edema (complications, drug therapy, metabolism)
• Female
• Humans
• Liver Cirrhosis (complications, drug therapy, metabolism)
• Liver Diseases (complications, drug therapy, metabolism)
• Male
• Middle Aged
• Serum Albumin (metabolism)
• Tolvaptan (blood, pharmacokinetics, therapeutic use)
• Treatment Outcome